Clinical Trials
44 trialsBrodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
Istituto Oncologico Veneto IRCCS
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
EARN
Washington University School of Medicine
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Tvardi Therapeutics, Incorporated
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
DUET-3
Xencor, Inc.
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
UPLIFT
Massachusetts General Hospital
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
DUET-4
Xencor, Inc.
CheckMate 76U
Bristol-Myers Squibb
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
DUET-2
Xencor, Inc.
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
ONCOPRO
Hospices Civils de Lyon
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
National Institutes of Health Clinical Center (CC)
EPAC
Stanford University
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
OrienGene Biotechnology Ltd.
Safety Study of Modified Vaccinia Virus to Cancer
University of Pittsburgh
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
Northwest Biotherapeutics
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
National Institutes of Health Clinical Center (CC)
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Study of NS-9 in Patients With Liver Metastases
NS Pharma, Inc.
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
FeRx